Ambiq Micro just posted its most explosive week since listing, and the catalyst was a Q1 earnings report that blew through every estimate on the Street.
The numbers landed May 12 and they were unambiguous. Adjusted EPS came in at $(0.25), well ahead of the $(0.36) consensus. Revenue hit $25.06M, topping the $21.49M estimate by roughly 17%. Q2 guidance was equally striking — the company sees Q2 sales of $31–32M against a Street estimate of just $25.7M. The stock closed at $66.37 on May 12, up 45% on the day and 64% on the week, and has more than doubled from a month ago.
The short positioning story is one of rapid capitulation. Short interest entered the week near 4.5% of the float — not extreme, but elevated for a stock of this size — and fell 24% week-on-week as shorts covered into the rally. The borrow market tells the same story: availability is ample, with cost to borrow running at just 0.67%, well below the brief spike above 1.8% in early April. The ORTEX short score has eased from 46 on May 4 to 37 as of May 12. That fall reflects a borrow market that shows no squeeze pressure — shorts are leaving, and there are plenty of shares available for anyone who still wants to bet against the name.
The Street has moved quickly. Needham raised its target from $48 to $70 while maintaining its Buy, and UBS's Timothy Arcuri lifted his target from $43 to $70 — though he held at Neutral, a notable split signal. Those two moves follow a September 2025 initiation wave, when Stifel, BofA, and UBS all opened coverage with targets in the low-$40s. The current consensus target of $64.60 is already nearly in line with the closing price, meaning the Street is scrambling to catch up with the move. The bull case — improving gross margins toward 53% by 2028, rising ASPs from the Apollo 5 and Atomiq product lines, and diversification away from China — is now substantially priced in at current levels. The bear case around China revenue decay remains real but is no longer a near-term surprise given the beat on revenue diversification.
Options traders are leaning emphatically bullish. The put/call ratio is 0.04, the lowest level in the past 52 weeks, and nearly two full standard deviations below the 20-day mean of 0.07. That means almost no one is buying downside protection — an unusual and concentrated expression of post-earnings confidence. The price-to-book has expanded to 7.3x, up over 4 points in the past month, a direct consequence of the price surge rather than any fundamental re-rate. PE and EV/EBITDA remain negative, reflecting a pre-profitability company still burning cash. Factor-ranked EPS surprise scores in the 82nd percentile, consistent with the beat pattern, while analyst recommendation divergence ranks in the 95th percentile — an unusually wide spread between bulls and bears on the Street.
Institutional ownership is still being built. T. Rowe Price, Vanguard, BlackRock, and Franklin Resources all added to positions in Q1 2026, alongside earlier-stage holders like Kleiner Perkins (9.7% of shares) and Atreides Management. AllianceBernstein added 161,000 shares through February. The ownership mix, skewed toward VC-era backers and fast-growing active managers, makes the share register more concentrated and potentially more reactive than a typical semiconductor stock of comparable size.
The next scheduled earnings event is May 22. That date is unusually close to the Q1 report — worth tracking to confirm the event type before treating it as a confirmed catalyst. With the stock now trading ahead of the consensus target and the short base nearly fully covered, the question heading into that date is whether the Q2 guide of $31–32M is the new anchor for analyst upgrades, or whether the post-earnings multiple expansion has already done the work.
See the live data behind this article on ORTEX.
Open AMBQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
